Precision NanoSystem

What Precision NanoSystem does

Precision NanoSystems is a Vancouver-based biotechnology tools company founded in 2010 that specializes in lipid nanoparticle (LNP) formulation technologies for nucleic acid delivery into genomic medicine applications, including mRNA vaccines, siRNA therapeutics, and CRISPR-based gene editing programs. Its core technology centers on proprietary ionizable cationic lipids that shift charge with pH, enabling strong nucleic-acid binding during formulation while remaining neutral at physiological pH to support efficient cellular delivery and endosomal escape. The product architecture is an integrated platform: the NanoAssemblr Ignite high-throughput microfluidic formulation system anchors the offering, supported by a reagent ecosystem built around the GenVoy-ILM ionizable lipid mix family, cell-type-specific kits (T Cell for mRNA, CD34+ HSC for hematopoietic stem cells), and an RNA delivery LNP kit, plus GMP-grade custom lipid libraries, cartridges and flow kits, and end-to-end formulation services.

The company monetizes across three streams: one-time reagent and kit sales, hardware/instrument sales of the NanoAssemblr platform with associated consumables, and professional formulation services including custom lipid sourcing and regulatory support. Customer segments are primarily pharmaceutical and biotechnology companies developing nucleic-acid therapeutics (with over 60 active UK LNP clinical trials cited as a downstream demand signal), supplemented by academic and research institutions. Distribution is product-led and globally channeled via Cytiva's e-commerce platform and bioprocessing sales organization following Cytiva's 2021 acquisition of the company, with Cytiva itself operating as part of the Danaher Corporation (NYSE: DHR). The company was previously venture-backed, raising approximately $37.6 million cumulatively across rounds led by 5AM Ventures, Telegraph Hill Partners, BDC Venture Capital, Accel-Rx, and the Government of Canada. Following the Cytiva transaction, Precision NanoSystems operates as a subsidiary rather than an independent reporting entity.

Name

Precision NanoSystem

Legal name

Precision NanoSystems

Website

https://precisionnanosystems.com

Company type

Private

Founded year

2010

Operating status

Acquired

Headcount range

11–50 employees

Short description

Precision NanoSystems, founded in Vancouver in 2010 and acquired by Cytiva in 2021, develops ionizable lipid nanoparticle (LNP) formulation technologies, including the NanoAssemblr Ignite platform and GenVoy-ILM reagent kits, sold to pharmaceutical and biotech companies developing mRNA vaccines, siRNA therapeutics, and CRISPR-based gene editing programs.

Ownership category

akta.pro rank

Product category

Lipid Nanoparticle Delivery Systems

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Lipid nanoparticle reagents
• Nanomedicine formulation systems
• MRNA delivery technologies
• Ionizable lipid kits
• Nucleic acid therapeutics

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. LNP Reagent and Kit Sales: Sale of off-the-shelf lipid nanoparticle formulation reagents, screening kits, and optimized LNP compositions to biopharmaceutical companies and researchers developing mRNA vaccines and RNA therapeutics.
2. Formulation Services: Custom formulation services and consulting for nanomedicine development, providing access to deep expertise and manufacturing frameworks for LNP-based therapeutics.
3. Instrument Sales: Sale of formulation systems including NanoAssemblr instruments and associated cartridges/flow kits for high-throughput LNP production.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Precision NanoSystems develops and sells lipid nanoparticle (LNP) formulation technologies for nucleic acid delivery, including ionizable lipid reagents and kits (GenVoy-ILM™), NanoAssemblr™ Ignite™ high-throughput formulation instruments, GMP-grade cartridges and flow kits, and custom LNP formulation services. The portfolio is used by biopharmaceutical companies and research institutions developing mRNA vaccines, siRNA therapeutics, and CRISPR-based gene editing therapies.

Product overview

Precision NanoSystems (acquired by Cytiva) offers an integrated platform of nanomedicine development technologies for genomic medicine applications. The portfolio centers on the NanoAssemblr™ Ignite™ formulation systems combined with a comprehensive reagent ecosystem including GenVoy-ILM™ ionizable lipid mixes and specialized cell-type kits (T cell, CD34+ HSC). The platform provides off-the-shelf LNP screening kits, custom lipid libraries (GLP/GMP grade), and formulation services enabling seamless transition from discovery through clinical manufacturing. The product architecture spans instrument platforms for high-throughput formulation, proprietary reagent kits for specific cell types and therapeutic modalities, and associated consumables and services for nucleic acid delivery optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• GenVoy-ILM™ Reagents and Kits Off-the-shelf ionizable lipid mix reagents and kits for lipid nanoparticle formulation screening and optimization in nucleic acid therapeutic development, used by biopharma companies and research institutions working on mRNA and RNA-based therapeutics.
• GenVoy-ILM™ T Cell Kits for mRNA Specialized lipid nanoparticle kits optimized for mRNA delivery to T cells, enabling targeted immune cell transfection for genomic medicine and cell therapy applications.
• RNA Delivery LNP Kit Complete kit for RNA-lipid nanoparticle formulation and delivery, designed for use with NanoAssemblr™ Ignite™ LNP systems to accelerate RNA-based drug development.
• CD34+ HSC LNP Kits Specialized lipid nanoparticle kits optimized for transfection of CD34+ hematopoietic stem cells, supporting cell and gene therapy development workflows.
• NanoAssemblr™ Ignite™ Formulation Systems High-throughput lipid nanoparticle formulation instruments enabling reproducible and scalable nanomedicine manufacturing for drug development pipelines.
• Lipid Nanoparticle Portfolio (Custom/GLP/GMP Lipids and Formulation Services) Comprehensive portfolio of custom, GLP, and GMP-grade ionizable lipids, pre-optimized LNP formulations, lipid library screening, and end-to-end formulation services for nucleic acid therapeutic development from discovery to clinic.
• Cartridges and Flow Kits Specialized consumables for nanoparticle formulation, including GMP-grade cartridges designed for precision micromachining and cleanroom assembly requirements used with NanoAssemblr™ formulation systems.
• LNP Formulation Services End-to-end formulation services including lipid library screening, GLP and GMP lipid sourcing, and regulatory support for nucleic acid therapeutic development programs.

Quantifiable outcome

• Demand for LNP formulation screening kits projected to double by 2030 relative to 2025 baseline in the UK market.
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• CytivacoreStrategic or Co-development Partner · 1 January 2021Cytiva acquired Precision NanoSystems, a Vancouver, Canada-based global leader in technologies, solutions, and services to support nanomedicine development for genomic medicine applications, including mRNA vaccines and therapeutics. The acquisition expanded Cytiva's lipid nanoparticle portfolio and nanomedicine formulation capabilities, providing customers with access to ionizable lipid mixes, pre-optimized LNP formulations, formulation systems, and deep expertise for establishing robust in-house LNP formulation and manufacturing frameworks.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Acuitas Therapeutics: Vancouver-based LNP delivery technology company that developed the lipid nanoparticle used in Pfizer-BioNTech's COVID-19 vaccine. Directly comparable as a specialized LNP delivery platform serving mRNA and nucleic acid therapeutic developers.
• Genevant Sciences: LNP delivery technology company spun out of Arbutus Biopharma, focused on lipid nanoparticle-based delivery for RNA therapeutics including siRNA and mRNA. Directly comparable product offering and customer base.
• Aldevron: Provides nucleic acid manufacturing services (plasmid DNA, mRNA, proteins) for gene therapy and cell therapy developers. Comparable as a CDMO serving nucleic acid therapeutic developers; now part of Danaher as well.
• TriLink BioTechnologies: CDMO specializing in mRNA, oligonucleotides, and plasmid DNA manufacturing for therapeutic developers. Comparable as a nucleic acid production services provider; acquired by Maravai LifeSciences.

Emerging players

• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery platform (LUNAR technology) for vaccines and therapeutics. Comparable as an LNP-enabled nucleic acid therapeutic developer.
• CureVac: mRNA technology company with proprietary LNP formulations for vaccines and therapeutics. Comparable as an LNP platform user/developer in nucleic acid delivery.

Broad incumbents

• BioNTech: Leading mRNA therapeutics company (partnered with Pfizer for COVID-19 vaccine) with proprietary LNP capabilities developed with Acuitas. Comparable end market (RNA therapeutics) but a customer/competitor rather than a tooling vendor.
• Moderna: Leading mRNA therapeutics and vaccines company with proprietary LNP delivery platform. Comparable end market, though operates as a customer/competitor rather than a reagent/tooling vendor.
• Sartorius AG: Major bioprocessing equipment and consumables supplier serving cell and gene therapy, mRNA, and biopharmaceutical manufacturers. Comparable as a Cytiva competitor serving similar bioprocessing end markets.
• Thermo Fisher Scientific: Global life sciences tools and services leader with significant presence in nucleic acid therapeutics manufacturing (Patheon, Brammer Bio). Comparable as a major bioprocessing and CDMO incumbent.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/precisionnano
• LinkedInlinkedin.com/company/precision-nanosystems-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision NanoSystem